Glycorex Transplantation AB (NGM:GTAB B) ROCE % : -21.73% (As of Dec. 2024)

View and export this data going back to 1999. Start your Free Trial

What is Glycorex Transplantation AB ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Glycorex Transplantation AB's annualized ROCE % for the quarter that ended in Dec. 2024 was -21.73%.

Glycorex Transplantation AB ROCE % Historical Data

The historical data trend for Glycorex Transplantation AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Glycorex Transplantation AB ROCE % Chart

Glycorex Transplantation AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

-8.82

-12.63

-9.82

-27.19

-23.88

Glycorex Transplantation AB Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial															-110.77	-27.44	-17.74	-28.64	-21.73

Glycorex Transplantation AB ROCE % Calculation

Glycorex Transplantation AB's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	-10.442	/	( ( (65.844 - 14.53)	+	(50.304 - 14.181) )	/ 2 )
	=	-10.442	/	( (51.314	+	36.123)	/ 2 )
	=	-10.442	/	43.7185
	=	-23.88 %

Glycorex Transplantation AB's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	-8.24	/	( ( (53.813 - 14.109)	+	(50.304 - 14.181) )	/ 2 )
	=	-8.24	/	( ( 39.704	+	36.123 )	/ 2 )
	=	-8.24	/	37.9135
	=	-21.73 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

Glycorex Transplantation AB (NGM:GTAB B) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Glycorex Transplantation AB ROCE % Related Terms

Thank you for viewing the detailed overview of Glycorex Transplantation AB's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Glycorex Transplantation AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Glycorex Transplantation AB (NGM:GTAB B) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

O33:Germany

Address

Solvegatan 41, Lund, SWE, 223 70

Website

http://www.glycorex.se

Glycorex Transplantation AB is a biotechnology company. The company is involved in the development, production, and sales of organ transplantation. Its product includes Glycosorb-ABO which facilitates the transplantation of organs over the blood group barriers. The group has more than 130 transplant centers in approximately 23 countries.

Glycorex Transplantation AB Headlines

No Headlines